Address: Beijing's xizhimen south street, xicheng district
The British garden 1 floor. Room 824
Zip code: 100035
Telephone: 010-58562339
Fax: 010-58562339
Email address: cngjzj@163.com
Web site (click on the url link directly left) :
http://www.cngjzj.com/
Blog (click on the url link directly left) :
http://blog.sina.com.Cn/CNGJZJ
To xizhimen south street, xicheng district building to the British garden route
L airport line 1
Take the airport shuttle from the airport, the dongzhimen station transfer to metro line 2 to xizhimen direction and get off at xizhimen station, from C outbound, go straight to the east 100 meters on the right side to xizhimen south street, north to walk to the t-junction namely to the British garden 1 floor downstairs.
L airport line 2
From the capital airport take airport bus to xidan, get off at no.22, take a taxi to xizhimen south street English garden 1 floor.
L bus subway near:
106 bus GuanYuan: 107 road, express way
Bus: xizhimen south road 387, 44 road, inner ring 800, 816 road, inner ring 820, 845 road
Che zhuang: subway line two
Xizhimen subway: metro line 2
Buses and attempts: 107 road, 118 road, 701 road
Buses and north zhuang: 209 road, 375 road, 392 road
Your position is：
Home >>
R&Dplatform >>
R&Dplatform
2013年10月29日
复制链接
打印
大 中 小
Lilly to invest 86 million dollars in research and development of traditional Chinese medicine cancer treatments
Source: medicine home network
Date: 2013/10/18
Invested by li ka-shing's Hutchison China MediTech company and lilly reached a about research and development of traditional Chinese medicine for the development of anti-cancer drugs fruquintinib agreement. Lilly will invest $86 million on the project. Is a kind of VEGFR1 Fruquintinib, 2, 3, inhibitor, is expected to treat a variety of cancers, the drug is currently in phase ii clinical study.
In recent years, many multinational companies to China's traditional Chinese medicine research expressed strong interest. Such as GSK set up specializing in traditional Chinese medicine research institutions in China, Johnson & Johnson has conducted similar investment in the field of infection, all these show the traditional Chinese medicine (TCM) bright prospect in drug research and development in the future.
Aerie Pharma biotechnology company recently decided to raise the total amount of the IPO to $84.5 million to support its research and development for the treatment of glaucoma medications. In September this year, the company has raised $58 million month, Aerie company has now decided to $12 to $14 a share price to sell 5.3 million shares. Aerie company plans to $34 million of that used in the treatment of glaucoma medications on the phase iii study of AR - 13324. At the same time to spend $5 million on match with AR - 13324 using PG324 phase ii study. With ipos have 39 biotechnology company, since its establishment, Aerie also no drug approved by the FDA, but the company says AR - 13324 is a potential treatment for glaucoma medications. Once listed, will be $4.5 billion worth of glaucoma treatment in the United States market share of a large cup of soup. But the specific situation how to also need time to test.
The original link: http://www.askci.com/news/201310/18/181441227534.shtml
